ANN ARBOR, MI--(MARKET WIRE)--Mar 10, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX:PP - News), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, today announced that the United States FDA has accepted a Pipex-supported, investigator-initiated, Investigational New Drug Application (IND) to conduct a double-blind, randomized, placebo-controlled Phase II clinical trial of oral flupirtine for the treatment of fibromyalgia, a rheumatic pain disease. Fibromyalgia affects an estimated 6 million people in the U.S. and recently Pfizer’s Lyrica® became the first FDA-approved treatment for fibromyalgia. The market for fibromyalgia treatments is expected to grow to several billion dollars annually in the coming years.
